榴莲视频

This cohort study uses a novel population-based methodology to estimate the proportion of older adult Medicare Fee-for-Service beneficiaries with cancer who participate in interventional cancer clinical trials.

This cohort study evaluates the validity linking fee-for-service Medicare claims and ClinicalTrials.gov through National Clinical Trial identifiers for patients with cancer enrolled in clinical trials.

This cross-sectional study examines where drugs were tested for US Food and Drug Administration approval and determines how commonly and quickly these drugs received marketing approval in the countries where they were tested, both overall and by country income level and geographical region.

This cohort study evaluates the differences in survival, duration of therapy, and treatment patterns between clinical trial patients and older adults with Medicare receiving cancer drugs for metastatic solid cancers in usual practice.

This cross-sectional study uses data from the IBM MarketScan Commercial Database to examine the association between increases in wholesale list prices of branded medications and amounts paid by patients and insurers for the same drugs.

This cross-sectional study examines the usage rates and trends of shorter vs longer radiation regimens for breast cancer and prostate cancer treatments in the US.

This study describes health services offered by USNWR 鈥渂est hospitals鈥� in executive physical packages, daylong comprehensive evaluations offering testing and screening of wealthy individuals and corporate leaders.

In this Viewpoint, Peter Bach and colleague Stacie Dusetzina question the assumption underlying a 2019 proposed federal rule change to eliminate drug manufacturer rebates to pharmacy benefit managers (PBMs) as a way to decrease prescription drug prices, and they propose more extensive restructuring, including a cap on out-of-pocket spending for Medicare Part D beneficiaries, to better control drug costs and save patients money.

In this Viewpoint, the authors review Medicare & Medicaid Services 340B Payment program and recent rules to curtail expansion of drug discounts beyond serving poor patients.

This Viewpoint discusses a 鈥淣etflix鈥� subscription model of drug payment being investigated by Louisiana for hepatitis C (HCV) drugs, in which a statewide coalition of payers would pay subscription fees over a fixed number of years for HCV drugs to treat all state residents and for efforts by the manufacturers to enhance treatment rates through patient outreach.

This review of pharmaceutical company press releases assesses how long it takes for complete data from potentially practice-changing industry-sponsored clinical trials in oncology to be published following the availability of important results.

This study examines the reliability of predictive markers of CT screening for lung cancer and its association with patient outcomes, including mortality.

In this Viewpoint, Peter Bach and colleagues distinguish 5 pricing reform proposals implied by the concept of value-based drug pricing and discuss the potential of each to ensure value in response to unsustainable drug price increases.

This study examines the nonresearch payments received by committee and board members of oncology clinical pathway vendors.

This study describes the effect of postoperative complications on hospital costs following total gastrectomy for gastric adenocarcinoma.

This Viewpoint uses FDA approval of tisagenlecleucel, the first chimeric antigen receptor T-cell (CAR-T) agent approved for human use, to discuss escalating drug prices for oncology therapies and the complex considerations of outcomes and value that should justify the pricing.